SPRAVATO® REMS Program Explained: What Every Patient Needs to Know

Spravato REMS Program Explained: What Every Patient Needs to Know

What Is REMS and Why Does It Exist?
Spravato REMS Requirements: The Rules
What "REMS-Certified" Actually Means
Finding a REMS-Certified Spravato Provider
Your REMS Treatment Day: Step-by-Step
The 2-Hour Monitoring Period Explained
Why Can't I Take Spravato Home?
REMS Patient Responsibilities
REMS for Different Diagnoses
Frequently Asked Questions
References & Resources

Key Takeaways

REMS (Risk Evaluation and Mitigation Strategy) is an FDA program controlling high-risk medications to ensure safe use
Spravato REMS requires: REMS-certified pharmacy, REMS-certified provider, REMS-certified clinic, patient enrollment, mandatory 2-hour office monitoring
Cannot take home: Spravato is distributed only to certified medical facilities; self-administration at home is strictly prohibited
2-hour monitoring mandatory: BP, heart rate, mental status, and dissociation monitored every 15–30 minutes during and after administration
Cannot drive post-dose: No driving for ≥5 hours after treatment; requires prearranged transportation home
Patient agreement required: All patients must sign REMS enrollment forms acknowledging risks and monitoring requirements
Why REMS exists: Dissociation (41% incidence), sedation, hypertension, and lack of long-term at-home data necessitate medical supervision
REMS is not a barrier: KwikPsych is REMS-certified and fully compliant; REMS ensures your safety, not denies you treatment

What Is REMS and Why Does It Exist?

The REMS Framework

REMS (Risk Evaluation and Mitigation Strategy) is an FDA program created to manage medications with serious risks that outweigh benefits in certain settings. The goal is safe medication use through additional safeguards beyond standard prescribing.

Think of REMS as "extra guardrails." While most medications need only a doctor's prescription and pharmacy dispensing, REMS medications require additional steps:

Prescriber training and certification
Pharmacy certification and special distribution
Patient education and enrollment
Structured monitoring and reporting

Why REMS for Spravato?

The FDA imposed REMS on Spravato (2019) because:

Novel rapid-acting mechanism: First intranasal antidepressant; limited long-term safety data at time of approval
Significant dissociation risk: 41% of patients experience dissociation vs. 9% placebo—unmonitored dissociation could lead to falls, accidents, impaired judgment
Blood pressure elevation: 10% of patients experience increased BP; unmonitored hypertension could lead to cardiovascular events
Sedation and impaired cognition: Patients are cognitively impaired post-dose; driving or operating machinery is unsafe
Drug interactions and contraindications: Complex interactions with other medications; certain psychiatric conditions (psychotic depression) contraindicate use
Insufficient home-use data: No evidence base for unmonitored, unsupervised home use

REMS is not punishment—it's a safety requirement ensuring structured medical oversight.

Spravato REMS Requirements: The Rules

What Does REMS Mandate?

Spravato REMS includes five key components:

1. REMS-Certified Pharmacies

Special distributor: Spravato is not available at regular pharmacies (CVS, Walgreens, etc.)
REMS pharmacy network: Medication distributed only through a network of REMS-certified specialty pharmacies
Direct delivery to clinic: Pharmacy delivers Spravato directly to the certified healthcare facility—never to the patient's home
Controlled inventory: Pharmacies track and report all Spravato distribution; inventory audits occur regularly

2. REMS-Certified Providers

Healthcare provider certification: Only certified physicians (MDs, DOs) or advanced practice providers (NPs, PAs) can prescribe and oversee Spravato
Training requirement: Providers must complete FDA-mandated REMS training on:
Indication and patient selection criteria
Dosing, monitoring protocols, and safety
Recognizing and managing adverse effects
When to withhold treatment (e.g., elevated BP)
Reporting adverse events
Certification maintenance: Periodic recertification required to maintain prescribing authority
Dr. Monika Thangada at KwikPsych: Board-certified psychiatrist, REMS-trained and certified

3. REMS-Certified Healthcare Facilities

Approved setting only: Administration must occur in a REMS-certified medical facility (office, clinic, hospital outpatient)
Facility requirements:
Trained nursing/clinical staff present during and after administration
Monitoring equipment available (BP cuff, pulse oximetry, cardiac monitoring if indicated)
Emergency medications and equipment on-site in case of hypertensive crisis or other adverse event
Private, safe environment for patient during 2-hour monitoring
KwikPsych Austin clinic: REMS-certified facility with full monitoring infrastructure

4. Mandatory Patient Enrollment

Patient agreement: All patients must be enrolled in the Spravato REMS Patient Registry
Informed consent: Patient must sign REMS forms acknowledging:
Understanding of the medication's risks and benefits
Acceptance of office-only administration requirement
Understanding of 2-hour monitoring requirement
Agreement not to drive for ≥5 hours post-dose
Agreement to report adverse events to provider
Registry tracking: FDA maintains database of all Spravato patients for safety surveillance
Annual re-enrollment: Patients continue REMS enrollment annually while on treatment

5. Structured Monitoring & Reporting

During-treatment monitoring: Vital signs, mental status, dissociation scale monitored per protocol (typically every 15–30 minutes)
Adverse event reporting: Any serious adverse events (severe hypertension, respiratory depression, severe dissociation, increased suicidality) reported to REMS database
Efficacy tracking: Provider documents treatment response, continuation decisions, and maintenance plans
Pharmacy coordination: Clinic coordinates with certified pharmacy; documented evidence of patient administration in certified facility

What "REMS-Certified" Actually Means

REMS Certification for Providers

A REMS-certified provider has:

Completed FDA-mandated training on Spravato risks, benefits, indications, contraindications, dosing, monitoring, and adverse event management
Demonstrated knowledge through certification exam or attestation
Agreed to comply with all REMS requirements in their practice
Committed to ongoing education and protocol updates
Maintained an active medical license and board certification in psychiatry or related field

Dr. Monika Thangada's Credentials:

M.D., psychiatrist
Board-certified by the American Board of Psychiatry and Neurology
Specialization in treatment-resistant depression
REMS-certified for Spravato administration
Experience administering 100+ Spravato doses

REMS Certification for Facilities

A REMS-certified facility has:

Met FDA infrastructure requirements (monitoring equipment, emergency medications, trained staff)
Established protocols for patient screening, informed consent, administration, and monitoring
Designated REMS coordinator responsible for compliance
Quality assurance program tracking adverse events, efficacy, and patient outcomes
Regular audits and inspections to ensure ongoing compliance
Insurance and liability coverage for Spravato administration

KwikPsych Austin:

REMS-certified medical facility for Spravato administration
Full infrastructure for safe, monitored treatment
Board-certified psychiatrist (Dr. Thangada) on-site
Trained clinical staff
Emergency protocols and medications available
Continuous quality monitoring

What REMS Certification Ensures for Patients

When you receive Spravato at a REMS-certified facility from a REMS-certified provider:

Standard of care: You're receiving treatment according to FDA-approved protocols
Safety: Medical staff trained in recognizing and managing Spravato-specific adverse events are present
Emergency preparedness: Equipment and medications to manage hypertensive crises, dissociation, respiratory issues are immediately available
Accountability: Your provider and facility are accountable to FDA; adverse events are tracked; poor outcomes investigated
Regulatory oversight: FDA periodically audits REMS-certified facilities to ensure compliance

Finding a REMS-Certified Spravato Provider

How to Identify REMS Providers

Option 1: Spravato Official Locator

Visit the official Spravato website (medication manufacturer's site)
Use their provider locator tool
Filters for location, insurance, and availability
Database updated regularly

Option 2: Insurance Provider Network

Contact your insurance company
Ask: "Which providers in my area are REMS-certified for Spravato?"
Insurance has lists of in-network REMS providers
Verify coverage for Spravato treatment while verifying provider

Option 3: Local Psychiatry Referrals

Ask your primary care doctor for referrals to psychiatrists offering Spravato
Contact local psychiatry associations or mental health organizations
Search "REMS-certified Spravato provider + [your city]"

Option 4: Directly Contact Clinics

Call psychiatry/mental health clinics
Ask: "Do you offer FDA-approved Spravato treatment?"
Verify REMS certification and Dr. credentials
Confirm insurance acceptance and scheduling

KwikPsych Austin: Your Local REMS Option

Location: 12335 Hymeadow Dr, Ste 450, Austin, TX 78750

Provider: Dr. Monika Thangada, M.D., Board-Certified MD Psychiatrist

REMS Status: Fully certified for Spravato administration

Services Offered:

Comprehensive psychiatric evaluation for TRD/suicidal ideation
FDA-approved Spravato treatment (acute and maintenance phases)
Medication management and optimization
Psychotherapy coordination
Integrated care planning

Insurance Accepted: Aetna, BCBS, Cigna, UnitedHealthcare, Superior/Ambetter, Baylor Scott & White, Oscar, First Health, Optum, Medicare, and self-pay

Contact: 737-367-1230

Your REMS Treatment Day: Step-by-Step

Before Your First Appointment: What to Expect

1. Initial Consultation (phone or in-person)

Describe symptoms, depression history, previous treatments
Discuss TRD criteria or suicidal ideation
Verify insurance and financial arrangements
Schedule comprehensive psychiatric evaluation

2. Comprehensive Psychiatric Evaluation

Duration: 60–90 minutes
Content:
Detailed depression history (onset, severity, previous treatment trials, response)
Suicidality assessment (if applicable)
Complete medical history, medications, allergies, substance use
Baseline vital signs (BP must be ≤140/90)
Baseline cognitive screening
Review of contraindications (psychotic depression, uncontrolled HTN, active substance use)
REMS Education:
Explanation of REMS program and why it exists
Discussion of office-only administration and monitoring requirements
Review of potential adverse effects (dissociation, BP elevation, sedation)
Explanation of no-driving-post-dose rule
Overview of treatment schedule (acute phase, frequency, expected duration)
Informed Consent & REMS Agreement:
Patient signs REMS enrollment forms
Patient acknowledges understanding of risks, benefits, monitoring requirements
Patient commits to office-only treatment and transportation arrangements
Next Steps:
Schedule first Spravato administration (typically 3–7 days later)
Discuss medication changes or adjustments
Provide written education materials

Your First REMS Treatment Day: Timeline

Arrival (15 minutes early)

Check-in at front desk
Verify identity, insurance, contact information
Submit completed patient forms if not done at evaluation

Pre-Treatment Assessment (15–30 minutes)

Vital signs obtained: BP, heart rate, respiratory rate, oxygen saturation, temperature
Critical: If systolic BP >140 or diastolic >90, treatment is WITHHELD and rescheduled
Reason: Spravato increases BP in some patients; pre-dose elevation is contraindication
Provider brief re-assessment:
Any new symptoms, medication changes, recent substance use
Current mental status and suicidality (if applicable)
Any questions or concerns about REMS
Nasal anatomy assessment:
Check for nasal obstruction, polyps, or septal deviation
Ensure intranasal route is feasible
Patient re-reviews and signs treatment log
Reminder review: REMS agreement, no-drive rule, monitoring duration

Medication Preparation (5 minutes)

Spravato retrieved from secure medication storage
Dose confirmed (typically 56 mg or 84 mg based on protocol)
Dose prepared under direct provider observation
Patient identity verified before administration

Administration (5–10 minutes)

Patient positioned comfortably
Provider explains intranasal spray technique
Patient self-administers spray into each nostril (metered-dose applicator)
Healthcare provider directly observes the entire administration
Patient advised: "Medication will be absorbed through nasal mucosa; you may notice onset of effects within 5–20 minutes"

Post-Administration Monitoring: 120 Minutes

Minutes 0–30 (Frequent Monitoring)

Every 15 minutes:
Vital signs: BP, HR, O2 saturation
Mental status check: Orientation, memory, attention
Dissociation scale assessment (PCP scale or similar)
Subjective symptom review: "How are you feeling? Any dizziness, nausea, or anxiety?"

Minutes 30–120 (Standard Monitoring)

Every 30 minutes:
Vital signs: BP, HR
Dissociation and mental status reassessment
Safety check: "Are you comfortable? Any concerns?"

Continuous Throughout:

Patient remains in private, safe clinical environment
Call bell or communication available for immediate staff assistance
Healthcare provider or trained staff member continuously present or immediately available
No driving, machinery operation, or high-risk activities
Mild-to-moderate dissociation expected and normal:
"Floaty" feeling, slight depersonalization, altered perception
All dissociation expected to resolve by end of 2-hour monitoring period
If adverse events occur:
Elevated BP (severe): IV antihypertensive medication available
Severe dissociation: Reassurance, continued monitoring, medication if needed
Respiratory depression: Oxygen, assisted ventilation if indicated
Increased suicidality: Psychiatric intervention, safety planning update

End of Monitoring (120 minutes)

Final vital signs obtained
Final mental status assessment
Cognitive check: "What is today's date? Who is the president? Can you remember my name?"
Confirm full orientation and cognition intact before discharge
Patient assessed for safe ambulation
Discharge decision: Proceed with discharge only if:
BP stable and normal range
Fully oriented and cognitively intact
Dissociation completely resolved
No acute psychiatric concerns (suicidality, severe anxiety)

Post-Treatment: After Leaving the Clinic

Immediate (0–5 hours)

Cannot drive: No driving for minimum 5 hours post-administration
Responsible adult must pick you up: Cannot use Uber, taxi, or self-transport
Avoid alcohol & CNS depressants: Do not drink alcohol for 24 hours; avoid benzodiazepines if possible
Rest: Return home, rest, eat light meal if nausea resolved
Monitor symptoms: Note any lingering dissociation, BP elevation, unusual symptoms

24 Hours Post-Treatment

Any residual effects (mild sedation, vertigo) typically resolved
Return to normal activities as tolerated
Continue current antidepressants or other medications as prescribed
Contact clinic immediately if:
Severe headache, chest pain, or difficulty breathing
Suicidal ideation worsening
Severe or persistent dissociation
Any other concerning symptoms

Before Next Appointment (3–7 days later)

Document any side effects or improvements you notice
Continue taking antidepressants as prescribed
Arrange transportation for next appointment
Contact clinic with any questions or concerns

The 2-Hour Monitoring Period Explained

Why 2 Hours?

Clinical Rationale:

Dissociation onset: Dissociation begins 5–20 minutes post-administration and peaks at 30–60 minutes
Peak adverse effects: Most adverse events (hypertension, severe dissociation, sedation) occur within first 60–90 minutes
Safety window: 2-hour monitoring covers peak risk period, plus additional time to ensure full resolution before discharge
Cognitive recovery: By 90–120 minutes post-dose, most patients are fully oriented and cognitively intact
BP normalization: Blood pressure typically returns to baseline by 60–90 minutes; 2-hour monitoring ensures sustained stability

Empirical basis: Clinical trials demonstrated that 2-hour monitoring captures all significant adverse events and allows for safe discharge.

What Happens During the 2 Hours

Dissociation Timeline (typical patient):

5–10 min: Mild onset of dissociation; slight "floatiness"
20–30 min: Peak dissociation; 40–50% intensity; patient feels detached, perceives environment differently
45–60 min: Peak or beginning decline; patient may report dream-like state or out-of-body awareness
90–120 min: Dissociation nearly completely resolved; patient feels normal, alert, oriented

Vital Sign Timeline (typical patient):

Baseline: SBP 120 mmHg, HR 70 bpm
15–30 min: SBP rises to 135–145 mmHg (most commonly); HR increases to 80–90 bpm
45–60 min: Peak SBP (usually 135–150 mmHg); HR elevated
90–120 min: SBP begins returning to baseline; typically normal by end of monitoring

Mental Status Timeline (typical patient):

0–30 min: Oriented ×3 but dissociative; memory and attention slightly impaired
30–90 min: Oriented ×3; cognition may feel "fuzzy" or "slowed"
90–120 min: Fully oriented ×3; cognition sharp; ready for discharge

Monitoring Advantages

Immediate intervention: If BP spikes dangerously, provider administers IV medication immediately—no delay
Safety net: Any severe adverse effect detected and managed in real-time
Patient reassurance: Knowing trained staff is continuously observing reduces anxiety about dissociative effects
Data collection: Each patient's vital signs and dissociation profile documented; informs future dosing decisions

Why Can't I Take Spravato Home?

The FDA Decision

The FDA mandates that Spravato cannot be dispensed for home use, even for patients who want it. The regulatory rationale:

Safety Concerns:

Unmonitored dissociation: Dissociation could lead to:

Falls or accidents (patient feels "detached," unaware of surroundings)
Impaired judgment (patient might attempt to drive, operate machinery)
Accidental injury (patient unaware of hazards)
Psychological distress (some patients find dissociation frightening without medical reassurance)

Unmonitored hypertension: BP elevation could lead to:

Hypertensive emergency (stroke, MI risk)
No immediate access to IV antihypertensives
Lack of monitoring = potential for severe complications before emergency services arrive

No evidence base: At time of FDA approval, insufficient data on:

Safety of unmonitored home administration
Patient compliance with self-monitoring
Risk profile of unsupervised use
Drug interactions in home environment

Abuse/diversion potential: Although esketamine low abuse potential vs. recreational ketamine:

Home access increases diversion risk (sharing with others)
Difficulty controlling inventory and secure storage in home setting
REMS aims to minimize recreational use

What About Patients Who Request Home Use?

FDA Position: Home use is not approved and not negotiable, regardless of patient preference.

Rationale: FDA regulations prioritize population safety over individual patient convenience. Even if you personally feel safe with home administration, FDA does not have sufficient evidence supporting safe home use in the broader population.

Alternative if Office Visits Are Difficult:

If you cannot access a REMS-certified office regularly due to:

Distance/transportation: Discuss telehealth psychiatric visits combined with in-office dosing; some providers allow video check-in before dosing
Work schedule: Discuss weekend or evening appointment availability
Mobility/disability: Some REMS clinics accommodate accessibility needs; discuss with provider

REMS Patient Responsibilities

What the REMS Program Requires From You

When you enroll in Spravato REMS treatment, you agree to:

1. Provide Informed Consent

Sign REMS agreement forms acknowledging:
You understand Spravato's risks and benefits
You understand office-only administration requirement
You accept mandatory 2-hour monitoring
You understand dissociation, BP elevation, and other adverse effects may occur
You will not drive for ≥5 hours post-dose
You will report adverse events to your provider

2. Keep Regular Appointments

Acute phase: Attend twice-weekly appointments (4 weeks minimum; 8+ doses)
Continuation phase: Weekly or scheduled appointments if continuing treatment
Maintenance phase: Monthly or per-provider-determined schedule for long-term management
Cancellations: Notify provider if you cannot attend; reschedule promptly

3. Abstain From Driving Post-Dose

No driving for ≥5 hours after Spravato administration
Arrange transportation: Have a responsible adult pick you up; pre-arrange before appointment
Alternative: Public transportation, rideshare services (but you cannot operate vehicle yourself)

4. Disclose All Medications & Substances

Complete medication list: Provide current medications, supplements, over-the-counter drugs
Substance use disclosure: Inform provider of alcohol, cannabis, or other substance use
Drug interactions: Discuss benzodiazepines, stimulants, opioids (may interact with Spravato)

5. Report Adverse Events

Notify provider immediately of:
Severe dissociation, anxiety, or panic
Severe hypertension or chest pain
Respiratory difficulty
Worsening suicidality
Any serious adverse effects
Follow-up communication: Participate in provider follow-up if adverse event reported

6. Comply With Monitoring

Cooperate with vital signs monitoring during and after administration
Participate in dissociation and mental status assessments
Remain in clinic during entire 2-hour monitoring period (no leaving early)
Answer provider questions honestly about symptoms, side effects, response

7. Don't Share or Divert Medication

Spravato is a controlled medication (REMS)
Do not share with others, sell, or divert to non-medical use
Medication is for your use only under medical supervision

REMS for Different Diagnoses

REMS for Treatment-Resistant Depression (TRD)

Indication: MDD failing ≥2 antidepressant trials
Dosing: 56 mg or 84 mg, twice weekly × 4 weeks (acute phase)
Monitoring: Standard 2-hour post-administration monitoring
REMS requirements: Full REMS program applies
Approved as: Monotherapy or adjunctive therapy

REMS for Acute Suicidal Ideation/Behavior

Indication: MDD with active suicidal ideation or recent suicide attempt/behavior
Dosing: 84 mg, intranasal, combined with antidepressant
Frequency: Can be dosed as frequently as daily during acute crisis
Monitoring: Same 2-hour post-administration monitoring required
REMS requirements: Full REMS program; may be expedited in acute inpatient settings
Special consideration: Psychiatric hospitalization may be concurrent; Spravato can be administered in inpatient psychiatric units if REMS-certified

Important Note

REMS requirements are identical regardless of diagnosis or severity. Whether you have TRD or acute suicidal ideation, the same REMS safeguards apply.

Frequently Asked Questions About REMS

1. Is REMS punishment or a barrier to treatment?

No. REMS is a safety requirement, not punishment. Think of it like regulations requiring airport security screening before flights—it protects everyone. REMS ensures:

You're receiving FDA-approved treatment from a trained provider
Your clinic has emergency equipment and protocols ready
Your vital signs and mental status are monitored during high-risk period
Any adverse events are documented and reported

REMS is your protection, not a barrier. Many patients find the structured monitoring reassuring.

2. Do all REMS-certified clinics offer the same treatment?

Mostly yes, with minor variations:

REMS requirements identical: All certified providers follow same FDA dosing, monitoring, and patient enrollment protocols
Minor differences: Some clinics may use different dissociation scales, slightly different monitoring intervals (15 vs. 30 min), or different medication adjustment protocols
Quality variations: Some clinics may offer more comfortable environments, more experienced staff, better integration with psychotherapy—but safety protocols standardized

3. Can I switch REMS providers?

Yes, but coordination is important:

Notify original provider: Inform them you're transferring care
Obtain records: Request your baseline evaluation, dosing history, response documentation
Provide to new provider: New provider needs your treatment history for informed dosing decisions
REMS re-enrollment: You remain in REMS; enrollment transfers automatically to new provider
Avoid gaps: Try to schedule first appointment with new provider before stopping at original clinic

4. What if I move to a different state or city?

Locate new REMS provider in your new location (use provider locator tools)
Obtain records from your current provider
Schedule evaluation with new provider
REMS enrollment transfers; you don't re-enroll from scratch

If no REMS provider available in new location: This is a challenge. Options:

Discuss with current provider about long-distance telehealth visits + local nursing administration (some clinics offer this)
Consider alternative treatments (TMS, IV ketamine, ECT) available in your area
Explore whether new location has ketamine clinic as alternative

5. What if I'm pregnant or planning pregnancy?

Spravato safety in pregnancy is unknown. FDA guidance:

Avoid if possible: Unknown risks to fetus
If taking Spravato pre-pregnancy: Discuss timing of discontinuation with psychiatrist
If pregnant and already on Spravato: Do NOT abruptly stop; work with psychiatrist and OB/GYN on safe management plan
REMS enrollment: Pregnant patients not typically enrolled unless acute suicidality makes benefits outweigh risks

Always discuss pregnancy plans with your psychiatrist before starting Spravato.

6. How long do I have to stay enrolled in REMS?

Duration:

During active Spravato treatment: Entire time you're receiving doses
After discontinuation: REMS enrollment typically ends when Spravato treatment ends
Re-activation: If you restart Spravato after a break, you re-enroll in REMS

Average enrollment: 3–12 months for acute + continuation phases; longer if maintenance treatment continued.

7. Does REMS cost extra?

No. REMS monitoring and administration costs are included in your Spravato dose cost ($179 self-pay at KwikPsych; covered by insurance). REMS itself doesn't add extra fees beyond standard treatment costs.

The REMS program and FDA requirements change periodically. Information in this article is current as of March 2026. Verify current REMS requirements with your provider or at FDA.gov.

References & Resources

FDA REMS Official Information

FDA. (2020). Risk Evaluation and Mitigation Strategy (REMS) for Spravato. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/rems
Spravato Official REMS Webpage. https://www.spravatorems.com/

Spravato Prescribing Information

U.S. Food and Drug Administration. (2019). Spravato (esketamine) Nasal Spray: Full Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243s000lbl.pdf

Clinical Monitoring Protocols

Canuso, C. M., et al. (2018). "Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study." American Journal of Psychiatry, 175(7), 620–630.
Popova, V., et al. (2019). "Efficacy and Safety of Flexibly-Dosed Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study." American Journal of Psychiatry, 176(6), 428–438.

REMS Regulatory Framework

Ionescu, D. F., et al. (2021). "Conceptual and Technical Considerations for Implementing Intravenous Ketamine in Psychiatry." JAMA Psychiatry, 78(7), 747–750.

Patient Education Resources

National Institutes of Mental Health (NIMH). (2024). Esketamine for Treatment-Resistant Depression. https://www.nimh.nih.gov/
American Psychiatric Association. Patient Information: Esketamine for Depression. https://www.psychiatry.org/